RedHill Biopharma (RDHL) Net Margin (2012 - 2023)

RedHill Biopharma (RDHL) has reported Net Margin for 12 consecutive years, with 3280.68% the latest figure, recorded in Q2 2023.

• On a quarterly basis, Net Margin rose 324467.0% year-over-year to 3280.68% in Q2 2023; TTM through Jun 2023 was 111.91%, a 3782.0% increase from a year earlier, with the FY2025 full-year figure at 150.0%, down 4720.0% from the prior year.
• Net Margin was 3280.68% for Q2 2023 at RedHill Biopharma, up from 220.03% in the prior quarter.
• Over five years, Net Margin peaked at 3280.68% in Q2 2023 and troughed at 658.08% in Q4 2021.
• A 5-year average of 368.88% and a median of 67.81% in 2020 frame the typical range for Net Margin.
• Across the five-year window, Net Margin sank 149215 bps in 2021 and jumped 324467 bps in 2023, its largest moves.
• Over 5 years, Net Margin stood at 744.47% in 2019, then plunged by 91 bps to 70.29% in 2020, then tumbled by 1036 bps to 658.08% in 2021, then gained by 17 bps to 543.22% in 2022, then soared by 704 bps to 3280.68% in 2023.
• The last three Net Margin figures came in at 3280.68% (Q2 2023), 220.03% (Q1 2023), and 543.22% (Q4 2022), per Business Quant data.